Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Midwest · Kansas
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in Wichita (400,000 residents, 650,000 metro). Kansas has not expanded Medicaid (as of 2025); KanCare covers T2D GLP-1s with prior auth.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in Wichita →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in Wichita →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in Wichita →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in Wichita →
Wichita is a midwest-region city with a population of 400,000 (650,000 in the broader metropolitan area). Kansas has not expanded Medicaid under the Affordable Care Act, which limits low-income adults' access to GLP-1 coverage; many uninsured residents rely on manufacturer savings programs or compounded options instead.
Statewide, notable health systems include University of Kansas Health System.
Kansas's Medicaid program is KanCare. Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.